Incyte Corporation vs Trade Desk Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Trade Desk Inc trades at $13.49 (market cap $6.37B). The key difference: Incyte Corporation is far larger — about 3.9× Trade Desk Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| INCY | TTD | |
|---|---|---|
Market Cap | $24.54B | $6.37B |
Sector | Health | Technology |
52-Week High | $129.93 | $55.36 |
52-Week Low | $81.61 | $13.39 |
Enterprise Value | $20.04B | $5.32B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →